Previous studies suggested that the SUMO4 gene, located in the IDDM5 interval on chromosome 6q25, was associated with type I diabetes (T1D) and several other autoimmune diseases. Subsequent analyses of the SUMO4 variants with T1D suggested that the association was stronger and more consistent in the Asian populations. In addition, considerable heterogeneity has been observed in the Caucasian populations. In this report, a 40-kb genomic interval including the SUMO4 gene was tagged with 15 single-nucleotide polymorphisms. A total of 2317 affected sib-pair families from the Type I Diabetes Genetic Consortium were genotyped using both the Illumina and Sequenom genotyping platforms. In these Caucasian families, we found little evidence supporting an association between SUMO4 and T1D.
Introduction
SUMO4 is a member of a highly conserved family of genes that encode small ubiquitin-related modifiers (SUMO). 1 The process to attach SUMO to proteins is known as sumoylation. The sumoylation system, initially characterized in 1996, 2 is a critical protein modification system found in all eukaryotic kingdoms. 3, 4 Sumoylation is a reversible modification involved in a variety of important processes of eukaryotic cells. Sumoylation seems to be a highly selective process both in terms of the choice of substrates and the timing of the modification, which is probably related to the maintenance of cellular homeostasis and the defensive response to stress or inflammatory insults. 5, 6 SUMO4 has a major function in NFkB and JAK/STAT signaling pathways and can regulate the activity of other critical immune molecules such as AP-1. 1, 5, 6 SUMO4 is located in the IDDM5 interval on chromosome 6q25, a type I diabetes (T1D) candidate region supported by numerous linkage studies. Multiple singlenucleotide polymorphisms (SNPs) surrounding the SUMO4 gene have been shown to be associated with T1D. 1 The associated SUMO4 SNP rs237025 has a single base-pair change (A-G) that causes an amino-acid change from methionine (M) to valine (V) at position 55 (M55V) in exon 1 of the gene. This SNP was strongly associated with T1D; further, the SNP is a potential 'causal variant' as the M55V substitution seemed to influence NFkB activity. 1, 6 Subsequently, this initial observation was a subject of intensive debate because of the failure to replicate the association in several Caucasian populations. [6] [7] [8] [9] Since the initial report, a number of studies have also revealed significant associations between SNPs in SUMO4 with other autoimmune diseases, [10] [11] [12] [13] [14] type II diabetes, 15 and diabetic complications. 16, 17 These studies have provided unambiguous evidence supporting a critical function of SUMO4 in many inflammatory diseases.
Several important questions concerning T1D and other disease associations with SNPs in SUMO4 remain to be addressed. One of the most important questions is why the SUMO4-T1D association is relatively strong in Asian populations, whereas the association evidence is inconsistent or undetectable in many Caucasian populations. The second question is whether the candidate SUMO4 (M55V) SNP is the only functional variant in the IDDM5 region. In the Type I Diabetes Genetic Consortium (T1DGC) Rapid Response project, 15 SNPs in the SUMO4 region were genotyped using the Illumina and the Sequenom platforms. Here, we report the data analysis on a worldwide collection of 2317 T1D affected sib-pair families from multiple populations of Caucasian ethnicity.
Results
A total of 2317 families were genotyped for 15 SNPs in the SUMO4 region (Supplementary Table 1 ) using both the Illumina and Sequenom platforms. The average call rate was 99.5% for the Illumina platform and 98.6% for the Sequenom platform. The average agreement of the genotype calls between the two platforms is 98.6% when the SNP rs237032 (agreement ¼ 33%) is excluded from analysis. The agreement for 4 of the 14 SNPs (Supplementary Table 1 ) is below 97% (average ¼ 95.8%). Although the agreement rates between platforms seem to be good, they may not be sufficient for association studies when the effect size of the genes is very small. The poor inter-platform agreement for the rs237032 and rs652921 SNPs (Supplementary Table 1 ) seems to be due to the poor call rates, resulting in significant deviation from Hardy-Weinberg equilibrium in the Sequenom data. Combining the genotype call rates and HardyWeinberg results, it seems that the Illumina platform may perform slightly better for the SUMO4 SNPs.
Pedigree disequilibrium test analysis was first performed over all families in the T1DGC dataset (Table 1) . Three SNPs (rs7742990, rs237032, and rs236999) had P-values o0.05 in the Illumina data, but only one of these three SNPs (rs236999) was marginally significant (P ¼ 0.07) in the Sequenom dataset ( Table 1) . Analysis of the data by source of the family collection also revealed several SNPs with marginally significant P-values in the Illumina panel for the British Diabetes Association and North America datasets (Supplementary Table 2 ). The earlier studied SUMO4 rs237025 (M55V) SNP showed significant associations with T1D in the British Diabetes Association dataset for both Illumina (P ¼ 0.02) and Sequenom (P ¼ 0.04).
We next examined association between T1D and SUMO4 SNP genotypes with respect to the interaction with HLA genotypes using a logistic regression model. The majority of the T1DGC affected sib-pair family members had been earlier typed for HLA-DR alleles. Family members were grouped into three HLA categories (HLA-DR4/4, -DR4/X, and -DRX/X, in which 'DRX' DR4). As shown in Table 2 , the rs366905 SNP showed a significant association with T1D (Po0.05) in both the Illumina and Sequenom datasets. The rs366905 SNP also exhibited a marginally significant association with T1D that depended on HLA-DR4 genotype (DR4/4, DR4/X, DRX/X). The rs480034 SNP also showed evidence of significant association with T1D in both panels overall as well as with inclusion of HLA-DR4 genotype. The greatest contributor to the association seems to be in the DR4/4 subgroup (data not shown). The linkage disequilibrium (LD), measured by R 2 value, was calculated for all marker pairs and shown in Figure 1 . Although there are strong LD between some markers pairs, there is no strong LD for this 45 kb region. This type of LD pattern is very unusual.
Discussion
This large T1DGC dataset failed to provide strong evidence for association between T1D and SNPs in the SUMO4 region in Caucasian affected sib-pair families. These results further support that there is no evidence for association between SUMO4 SNPs and T1D in Caucasian Analyses of multiple SNPs in SUMO4/IDDM5 region in affected sib-pair families with T1D
populations. In contrast, SUMO4 is consistently associated with T1D in the Asian populations. 1, 6, 13, [18] [19] [20] Furthermore, SUMO4 is associated with several other inflammatory diseases including rheumatoid arthritis, [10] [11] [12] [13] autoimmune thyroid disease, 13 autoimmune Behcet's disease, 14 diabetic retinopathy in T1D, 17 T2D, 15 and nephropathy in T2D. 16 These studies suggested that SUMO4 is involved in many inflammatory diseases in both Asians and Caucasians.
A key question remains why the association between SUMO4 SNPs and T1D is only observed in some Caucasian datasets, but not in others? The simplest interpretation of the data is that SUMO4 is not involved in T1D susceptibility in Caucasians and the observed association evidence is purely because of chance. One potential hypothesis is that a gene (SUMO4) is involved in the risk of disease (T1D) only in certain ethnic groups, a hypothesis that we do not believe. An alternative explanation that we favor more is that the differences in association of SNPs in SUMO4 and T1D between populations could be explained by differences in the patterns of LD between populations. This is a distinct possibility given the unusual LD pattern in this region. A third explanation is that SUMO4 may only be an important risk factor in a subset of T1D patients and that the frequency and/or sampling of the patient subsets may determine whether a significant association can be observed. This interpretation is consistent with the weak and marginally significant associations observed in the majority of the Caucasian datasets, including this T1DGC dataset. These results are also consistent with the observations that association may be improved in Caucasian and Asian datasets after stratification with other genetic factors (such as HLA) 13, 21 or other autoimmune diseases. 13 However, the main genetic or environmental factors that may interact with SUMO4 remain to be identified. Ultimately, the true function of SUMO4 in T1D susceptibility can only be understood when all the genetic factors and their interactions with other genes and environmental risks are fully characterized.
Materials and methods

Patients and methods
SNPs were genotyped in a set of 11 250 individuals comprising 5047 T1D affected individuals collected throughout the world by the T1DGC. In total, there are 2317 T1D nuclear families, of which 2126 families were of European origin and 191 were Asian-Pacific. Genotyping was carried out using the Illumina Infinium II HumanHap550 BeadChip technology (Illumina, Inc., San Diego, USA) as well as Sequenom high throughput SNP genotyping platform. Details of the patient samples and the quality control procedures can be found in this volume (Brown et al. 22 ).
Statistical analysis
Tests for Hardy-Weinberg frequencies were conducted by randomly sampling one normal subject from each pedigree. These tests were conducted using SAS v9.1. UNPHASED v2.404 was used with the PDTPHASE option to conduct the pedigree disequilibrium test analyses. 23 Single marker, and two-and three-marker haplotype association tests were used. Generalized estimating equations were used to analyze logistic regression models in examining interactions with HLA genotypes. The general model included SNP genotype, the number of HLA-DR4 alleles, and contributing cohort, as well as interactions among these three variables. Pedigree within cohort was used as the variable that accounted for repeated measures. These analyses were conducted using the Proc GENMOD procedure in SAS v9. 1 . Haploview was used to analyze LD. 24 
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